Press Releases 2014

December 16, 2014
Galapagos regains full rights to GPR84 inhibitor GLPG1205
View English version - Bekijk Nederlandse versie

December 12, 2014
Galapagos selects second component of its investigational cystic fibrosis combination treatment
View English version - Bekijk Nederlandse versie

 December 9, 2014
Galapagos increases share capital through warrant exercises
 View English version - Bekijk Nederlandse versie

November 24, 2014 
Galapagos completes recruitment for Darwin 2 monotherapy study with GLPG0634 (filgotinib) in RA
View English version - Bekijk Nederlandse versie

November 17, 2014
Galapagos presents clean drug-drug interaction profile with GLPG0634 (filgotinib) at ACR 2014
View English version - Bekijk Nederlandse versie

November 12, 2014
Galapagos completes recruitment for Darwin 1 study with GLPG0634 (filgotinib) in RA
 
View English version - Bekijk Nederlandse versie

November 6, 2014 
GSK discloses good efficacy in psoriasis with GSK2856184
View English version - Bekijk Nederlandse versie

October 27, 2014 
Galapagos and Calchan collaborate on osteoarthritis research, £2.4 million grant awarded by Innovate UK
View English version - Bekijk Nederlandse versie

October 20, 2014
Galapagos discloses novel target and presents favorable Phase 1 data for GLPG1205 at UEG Week
View English version - Bekijk Nederlandse versie

October 17, 2014
 
Galapagos creates new warrant plan
 
View English version - Bekijk Nederlandse versie

 October 15, 2014
Bart Filius joins Galapagos as CFO
View English version - Bekijk Nederlandse versie

 October 9, 2014
Galapagos presents novel cystic fibrosis combination therapy at NACFC
View English version - Bekijk Nederlandse versie

 September 25, 2014
Galapagos increases share capital through warrant exercises
View English version - Bekijk Nederlandse versie

 September 18, 2014
Galapagos reports high participation rate in long term extension study with GLPG0634 in RA patients
View English version - Bekijk Nederlandse versie

August 8, 2014
Galapagos cash position of €232 M provides solid basis for R&D pipeline investment
View English version - Bekijk Nederlandse versie

 August 5, 2014
Galapagos receives milestone in osteoarthritis alliance with Servier
View English version - Bekijk Nederlandse versie

July 25, 2014
Galapagos creates new warrant plan
View English version - Bekijk Nederlandse versie

July 23, 2014
MorphoSys and Galapagos advance joint antibody program in inflammatory diseases into preclinical development
View English version - Bekijk Nederlandse versie

 July 4, 2014
Galapagos raises €1.9 million through warrant exercises
View English version - Bekijk Nederlandse versie

 July 1, 2014
Galapagos initiates Phase 1 study with GLPG1690, triggering €6.6 M milestone in the alliance with Janssen Pharmaceutica NV
View English version - Bekijk Nederlandse versie

 June 17, 2014
Galapagos cystic fibrosis program progresses towards therapy for largest patient group
View English version - Bekijk Nederlandse versie

 May 12, 2014
Galapagos to hold Annual R&D Update on 17 June 2014 in New York
View English version - Bekijk Nederlandse versie

 April 30, 2014
Invitation to the Extraordinary General Shareholders' Meeting to be held on 19 May 2014
View English version - Bekijk Nederlandse versie

April 28, 2014
Galapagos announces management change
View English version - Bekijk Nederlandse versie

April 17, 2014
GSK2586184 meets primary endpoint in Phase 2a psoriasis study
View English version - Bekijk Nederlandse versie

April 10, 2014
Galapagos raises €2.4 million through warrant exercises
View English version - Bekijk Nederlandse versie

 April 1, 2014
Charles River Laboratories and Galapagos complete transaction
View English version - Bekijk Nederlandse versie

March 28, 2014
Invitation to the Annual and Extraordinary General Shareholders' Meetings to be held on 29 April 2014
View English version - Bekijk Nederlandse versie

March 21, 2014
Euronext Amsterdam to become Market of Reference for Galapagos
View English version - Bekijk Nederlandse versie

March 18, 2014
Galapagos to present favorable pre-clinical data on GLPG1790, a selective ephrin receptor kinase inhibitor, at AACR in San Diego
View English version - Bekijk Nederlandse versie

 March 13, 2014
Charles River Laboratories to acquire Galapagos' Argenta and BioFocus service operations for up to €134 million
View webcast
View English version - Bekijk Nederlandse versie

March 7, 2014
Galapagos reports 2013 financial results
View webcast presentation
View English version - Bekijk Nederlandse versie
View Financial Tables - Bekijk Financiële Tabellen

 March 7, 2014
Galapagos receives €2 million from osteoarthritis alliance with Servier
View English version - Bekijk Nederlandse versie

February 28, 2014
Galapagos provides status update for GSK2586184 in GSK's psoriasis, lupus, and ulcerative colitis clinical studies
View English version - Bekijk Nederlandse versie

February 21, 2014
Galapagos to present GLPG0634 and GLPG0974 at International Conference on IBD
View English version - Bekijk Nederlandse versie

February 17, 2014
Galapagos completes patient recruitment in Proof of Concept study with GLPG0974 in ulcerative colitis
View English version - Bekijk Nederlandse versie

 February 3, 2014
Galapagos receives €2.3 million IWT grant for fibrosis research
View English version - Bekijk Nederlandse versie

January 29, 2014
First clinical centers opened for Phase 2 Crohn's study with GLPG0634
View English version - Bekijk Nederlandse versie

January 13, 2014
Galapagos receives €2.9 million IWT grant for cystic fibrosis research
View English version - Bekijk Nederlandse versie

 January 6, 2014
Van Herk Investments notify of 5.3% shareholding in Galapagos
View English version - Bekijk Nederlandse versie

December 19, 2014
Galapagos initiates first Phase 1 study in cystic fibrosis and will receive milestone payment from AbbVie
 
View English version - Bekijk Nederlandse versie

Share to Facebook Share to Twitter Share to LinkedIn Share via Email

© Copyright 2014 Galapagos NV | Disclaimer | General Purchase Terms 

 
Test